LGALS3 and cancer: These synthetic peptides, although not modified with any galactose residues, were reported to bind to the galectin-3 CRD and inhibit galectin-3-TF interaction, and prevent galectin-3-mediated cancer cell adhesion, aggregation in vitro and metastasis in vivo [52].